newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

  • Total product sales and commercial rights revenues for 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million).
  • Olverembatinib sales rose 81% year-over-year to US$62.2 million (RMB435.3 million) in 2025.
  • Lisaftoclax generated US$10.1 million (RMB70.6 million) in sales during the five months following its July 2025 launch.
  • Nine registrational Phase III clinical trials are currently in progress worldwide, including four cleared by the FDA and EMA.
  • All approved indications for Olverembatinib have been covered by China's National Reimbursement Drug List (NRDL) since January 2025.
  • The number of hospitals with Olverembatinib on formulary in Direct-to-Patient pharmacies reached 825 as of December 31, 2025.
  • Enrollment continues for POLARIS-1 (Ph+ ALL), POLARIS-2 (CML), and POLARIS-3 (GIST) trials for Olverembatinib.
  • Lisaftoclax received conditional approval from China's NMPA on July 10, 2025, for treating adult patients with CLL/SLL who have received prior BTK inhibitor therapy.
  • Enrollment continues for four global registrational Phase III trials for Lisaftoclax: GLORA, GLORA-2, GLORA-3, and GLORA-4.
  • The BTK degrader APG-3288 received IND clearance from the FDA and China's CDE in Q1 2026, with a Phase I study planned.
  • Total revenue for 2025 was US$82.1 million, a 41.5% decrease from 2024, primarily due to the absence of US$92.9 million in intellectual property revenue recorded in 2024.
  • Selling and distribution expenses increased 80.4% to US$50.6 million in 2025 due to expanded commercialization activities.
  • Research and development expenses increased 20.1% to US$162.7 million in 2025 driven by higher clinical trial costs.
  • The company reported a net loss of US$177.7 million for 2025 compared to US$55.6 million in 2024.
  • Cash and bank balances increased 95.9% to US$353.2 million as of December 31, 2025, following net proceeds from U.S. IPO and follow-on offerings.
  • An investor webcast was scheduled for March 26, 2026, with separate Mandarin and English language sessions.